United Therapeutics' Ralinepag Shows Strong Efficacy in PAH Study
Event summary
- Ralinepag reduced the risk of clinical worsening by 55% in PAH patients compared to placebo.
- The ADVANCE OUTCOMES study met its primary endpoint with statistical significance (hazard ratio 0.45).
- United Therapeutics submitted a New Drug Application for ralinepag to the FDA in June 2026.
- The Lancet published full results of the ADVANCE OUTCOMES study on July 29, 2026.
The big picture
United Therapeutics' positive ADVANCE OUTCOMES study results for ralinepag come at a time when the PAH treatment landscape is evolving with increasing demand for effective oral therapies. The study's success highlights the potential of prostacyclin pathway agonists in improving long-term outcomes for PAH patients, positioning United Therapeutics to compete with established treatments if regulatory approval is secured.
What we're watching
- Regulatory Approval
- Whether the FDA will approve ralinepag based on the positive ADVANCE OUTCOMES study results.
- Market Positioning
- How United Therapeutics positions ralinepag against existing PAH treatments in a competitive market.
- Long-term Efficacy
- The durability of ralinepag's clinical benefits in long-term use, especially in pretreated patients.
Related topics